Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
1.090
-0.080 (-6.84%)
Mar 31, 2025, 3:55 PM EDT - Market open

Silexion Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2013 FY 2012
Period Ending
Dec '13 Dec '12
Selling, General & Admin
0.240.17
Research & Development
1.120.79
Operating Expenses
1.360.95
Operating Income
-1.36-0.95
Interest Expense
-0-0
Interest & Investment Income
00.01
Currency Exchange Gain (Loss)
00.01
Pretax Income
-1.36-0.94
Net Income
-1.36-0.94
Net Income to Common
-1.36-0.94
Shares Outstanding (Basic)
00
Shares Outstanding (Diluted)
00
Shares Change (YoY)
16.10%-
EPS (Basic)
-81.80-65.74
EPS (Diluted)
-81.80-65.74
Free Cash Flow
-0.8-0.91
Free Cash Flow Per Share
-48.23-64.06
EBITDA
-1.36-0.95
D&A For EBITDA
00
EBIT
-1.36-0.95
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q